Drug Trial Radar · NCT06348199
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
555
Actual
Start
Mar 12, 2024
Primary completion
Mar 10, 2026
Study completion Aug 2027
Sponsor
- Lead sponsor
- Samsung Bioepis Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is: • How effective the study drug is Participants will receive either investigational product (SB27 or Keytruda) and chemotherapy every 3 weeks. Researchers will compare SB27 and Keytruda to see if SB27 works in the same way as Keytruda.
Conditions
- Non-small Cell Lung Cancer Stage IV
Interventions
SB27Drug
Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
KeytrudaDrug
Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) at Week 24Time frame: At Week 24
Locations
93 sites in 14 countries. Site status is shown where the registry gives one.
SB Investigative Site
Banja Luka, Bosnia and Herzegovina
SB Investigative Site
Mostar, Bosnia and Herzegovina
SB Investigative Site
Sarajevo, Bosnia and Herzegovina
SB Investigative Site
Curitiba, Brazil
SB Investigative Site
Florianópolis, Brazil
SB Investigative Site
Ijuí, Brazil
SB Investigative Site
Natal, Brazil
SB Investigative Site
Pelotas, Brazil
SB Investigative Site 1
Porto Alegre, Brazil
SB Investigative Site 2
Porto Alegre, Brazil
SB Investigative Site
Rio de Janeiro, Brazil
SB Investigative Site
Santo André, Brazil
SB Investigative Site
Batumi, Georgia
SB Investigative Site 1
Tbilisi, Georgia
SB Investigative Site 2
Tbilisi, Georgia
SB Investigative Site 3
Tbilisi, Georgia
SB Investigative Site 4
Tbilisi, Georgia
SB Investigative Site 5
Tbilisi, Georgia
SB Investigative Site 6
Tbilisi, Georgia
SB Investigative Site
Düsseldorf, Germany
SB Investigative Site
Halle, Germany
SB Investigative Site
Moers, Germany
SB Investigative Site
Neuss, Germany
SB Investigative Site
Bangalore, India
SB Investigative Site
Bhubaneswar, India
SB Investigative Site
Erandwane, India
SB Investigative Site
Hyderabad, India
SB Investigative Site 1
Jaipur, India
SB Investigative Site 2
Jaipur, India
SB Investigative Site
Mumbai, India
SB Investigative Site
Sūrat, India
SB Investigative Site
Udaipur, India
SB Investigative Site
Himeji, Japan
SB Investigative Site
Iwakuni, Japan
SB Investigative Site
Izumi, Japan
SB Investigative Site
Kawachi-Nagano, Japan
SB Investigative Site
Kobe, Japan
SB Investigative Site
Kochi, Japan
SB Investigative Site
Sagamihara, Japan
SB Investigative Site
Tachikawa, Japan
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.